secwatch.observer — SEC 8-K summary
======================================

Issuer:     Milestone Pharmaceuticals Inc. (MIST)
CIK:        0001408443
Form:       8-K
Filed at:   2025-03-28T23:59:59+00:00
Accession:  0001104659-25-029047
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA issues Complete Response Letter for etripamil PSVT NDA; no clinical issues raised
--------------------------------------------------------------------------------

- CRL focuses on CMC: additional nitrosamine impurity data and facility inspection required.
- No clinical safety or efficacy concerns cited by FDA for CARDAMYST (etripamil) nasal spray.
- Company plans to request a Type A meeting with FDA to discuss resubmission path.
- Cash, cash equivalents and short-term investments of $69.7M as of Dec 31, 2024.
- CEO expresses disappointment but remains committed to the program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1408443/000110465925029047/0001104659-25-029047-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1408443/000110465925029047/tm2510765d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-029047

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer